iBio, Inc. updated its corporate presentation, highlighting promising data for its anti-myostatin antibody IBIO-600, which showed a half-life of 40 to 52 days in non-human primates and potential human half-life of 130 days, along with positive results from an Activin E antibody study indicating significant weight loss effects.